RVMD · Revolution Medicines, Inc. · Webcasts, Transcripts & Audio
$159.82
-2.87 (-1.76%)
At close · Nov 18
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$34.57B
Shares
216.29M
Volume · Nov 18
2.34M
Avg daily vol (3M)
2.2M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Revolution Medicines, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Revolution Medicines, Inc. (RVMD), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-16
Revolution Medicines, Inc. (RVMD) November 16, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-10
Revolution Medicines, Inc. (RVMD) November 10, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-04
Revolution Medicines, Inc. (RVMD) Q3 2026 Earnings Call Transcript
Confident tone
Colorectal cancer program
Financial position and spending
Pancreatic cancer pipeline
Revenue
$197.56M
Diluted EPS
$-1.90
Gross margin
99.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-08-05
Revolution Medicines, Inc. (RVMD) Q2 2026 Earnings Call Transcript
Confident tone
Expanded Access Program (EAP)
Pancreatic cancer / PDAC launch
Broader pipeline / RAS(ON) inhibitors
Diluted EPS
$-3.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-05-31
Revolution Medicines, Inc. (RVMD) May 31, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
Revolution Medicines, Inc. (RVMD) Q1 2026 Earnings Call Transcript
Confident tone
RASolute 302 Phase 3 results in pancreatic cancer
Clinical and competitive uncertainties
Non-small cell lung cancer development
Diluted EPS
$-2.29
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-25
Revolution Medicines, Inc. (RVMD) Q4 2025 Earnings Call Transcript
Confident tone
RMC-6236 (daraxonrasib) combination strategies
Zoldonrasib development in PDAC
Daraxonrasib in pancreatic cancer (RASolute 302/303/304)
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Revolution Medicines, Inc. (RVMD) Q3 2025 Earnings Call Transcript
Confident tone
Daraxonrasib in pancreatic cancer (PDAC)
Combination strategies and resistance mechanisms
Efficacy and durability data
Revenue
$0
Diluted EPS
$-1.61
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Revolution Medicines, Inc. (RVMD) Q2 2025 Earnings Call Transcript
Confident tone
Pancreatic cancer program (daraxonrasib)
Non-small cell lung cancer (NSCLC)
Clinical collaborations and combinations
Diluted EPS
$-1.31
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Revolution Medicines, Inc. (RVMD) Q1 2025 Earnings Call Transcript
Confident tone
Non-small cell lung cancer strategy
RAS(ON) inhibitor portfolio
Pancreatic cancer development
Diluted EPS
$-1.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-26
Revolution Medicines, Inc. (RVMD) Q4 2024 Earnings Call Transcript
Confident tone
RAS(ON) inhibitor pipeline progress
Combination strategies
Pivotal/registrational trials execution
Revenue
$0*
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings Call Transcript
Confident tone
RMC-6236 in pancreatic cancer (PDAC)
Combination strategy and clinical collaborations
Non-small cell lung cancer strategy
Revenue
$0
Diluted EPS
$-0.94
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Revolution Medicines, Inc. (RVMD) Q2 2024 Earnings Call Transcript
Confident tone
RMC-6236 pancreatic cancer data and registrational plans
Combination studies and early-line expansion
RAS(ON) mutant-selective inhibitors (RMC-6291, RMC-9805)
Revenue
$0
▼ 100% YoY Diluted EPS
$-0.81
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Revolution Medicines, Inc. (RVMD) Q1 2024 Earnings Call Transcript
Confident tone
RMC-6236 combination regimens
RMC-6236 pivotal trial strategy
RMC-6291 and RMC-9805 mutant-selective inhibitors
Revenue
$0
▼ 100% YoY Diluted EPS
$-0.70
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-26
Revolution Medicines, Inc. (RVMD) Q4 2023 Earnings Call Transcript
Confident tone
RMC-6236 pivotal trial plans
Financial strength and runway
RMC-6291 G12C selective inhibitor
Revenue
$742,000*
▼ 95.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-06
Revolution Medicines, Inc. (RVMD) Q3 2023 Earnings Call Transcript
Revenue
$0
▼ 100% YoY Diluted EPS
$-0.99
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Revolution Medicines, Inc. (RVMD) Q2 2023 Earnings Call Transcript
Revenue
$3.82M
▼ 58.1% YoY Diluted EPS
$-0.92
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Revolution Medicines, Inc. (RVMD) Q1 2023 Earnings Call Transcript
Revenue
$7.01M
▼ 7.4% YoY Diluted EPS
$-0.72
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-27
Revolution Medicines, Inc. (RVMD) Q4 2022 Earnings Call Transcript
Revenue
$15.33M*
▲ 62.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-07
Revolution Medicines, Inc. (RVMD) Q3 2022 Earnings Call Transcript
Revenue
$3.36M
▲ 204.8% YoY Diluted EPS
$-0.87
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Revolution Medicines, Inc. (RVMD) Q2 2022 Earnings Call Transcript
Revenue
$9.12M
▲ 4.8% YoY Diluted EPS
$-0.82
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Revolution Medicines, Inc. (RVMD) Q1 2022 Earnings Call Transcript
Revenue
$7.58M
▼ 25.2% YoY Diluted EPS
$-0.78
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-11
Revolution Medicines, Inc. (RVMD) Q4 2021 Earnings Call Transcript
Revenue
$9.46M*
▲ 8.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Revolution Medicines, Inc. (RVMD) Q3 2021 Earnings Call Transcript
Revenue
$1.10M
▼ 91.3% YoY Diluted EPS
$-0.72
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-11
Revolution Medicines, Inc. (RVMD) Q2 2021 Earnings Call
Revenue
$8.70M
▼ 13.2% YoY Diluted EPS
$-0.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–25 of 25 webcasts
Key facts
CIK
1628171
CUSIP
76155X100
13F (30d)
719 filings
681 filers
Visit website
Investor relations